Armenta Bioscience ApS: Financial statements 2022
CVR: 42358444
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Armenta Bioscience ApS (CVR 42358444) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 7,084 and a net result of DKK 6,593. Equity in the 2022 report amounted to DKK 36,155. The solvency ratio was 66.8%.
- Gross Profit
- DKK 7,084
- Profit/Loss
- DKK 6,593
- Equity
- DKK 36,155
- Total Assets
- DKK 54,155
Keep an eye on Armenta Bioscience ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Armenta Bioscience ApS has published its interim report for the period April 28, 2021 – December 31, 2021.
About Armenta Bioscience ApS
Armenta Bioscience ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2021. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Gephion Bio ApS and Meat Tomorrow ApS. The management consists of Matias Heide Ankjær and David Valbjørn Christensen. The company's owners include Accelerace Invest II K/S, Kempf ApS and Niklis Holdings ApS. In 2025, the company reported a gross profit of DKK -676,873 and a net result of DKK -1,433,453 compared with DKK -1,393,964 the year before. Equity in the 2025 report amounted to DKK 1,283,993.